H Krankenberg1. 1. Zentrum für Gefäßmedizin, Abteilung Angiologie, Asklepios Klinikum Harburg, Eißendorfer Pferdeweg 52, 21075, Hamburg, Deutschland. h.krankenberg@asklepios.com.
Abstract
BACKGROUND: Peripheral artery disease (PAD) is often diagnosed in an advanced stage. Accordingly, revascularization is also performed late. OBJECTIVES: In this paper, the authors describe the progression to critical limb ischemia and cardiovascular risk. Revascularization for secondary prevention is explained. Revascularization strategies according to lesion location and complexity of the stenosis or occlusion are discussed. MATERIALS AND METHODS: The current guidelines and randomized controlled studies and meta-analyses are analyzed. RESULTS: PAD is associated with a considerable level of suffering and a high cardiovascular risk. Up to 20% of patients with claudicants will progress to critical limb ischemia. Progression and risk of mortality increase during the course of the disease. Improvement of walking ability by revascularization is a major goal of secondary prevention. In the femoropopliteal segment, drug-coated balloon (DCB) angioplasty and bare-metal stent (BMS) implantation are the methods of choice. In long lesions, spot-stenting should be preferred. For treatment of in-stent restenosis, DCB have proven their effectiveness. In severely calcified or dissected lesions, BMS are well suited. Infrapopliteal lesions should be revascularized to provide in-line flow to the foot through the target arterial path. According to current evidence, DCB or drug-eluting stents are more effective than plain old balloon angioplasty or BMS.
BACKGROUND:Peripheral artery disease (PAD) is often diagnosed in an advanced stage. Accordingly, revascularization is also performed late. OBJECTIVES: In this paper, the authors describe the progression to critical limb ischemia and cardiovascular risk. Revascularization for secondary prevention is explained. Revascularization strategies according to lesion location and complexity of the stenosis or occlusion are discussed. MATERIALS AND METHODS: The current guidelines and randomized controlled studies and meta-analyses are analyzed. RESULTS:PAD is associated with a considerable level of suffering and a high cardiovascular risk. Up to 20% of patients with claudicants will progress to critical limb ischemia. Progression and risk of mortality increase during the course of the disease. Improvement of walking ability by revascularization is a major goal of secondary prevention. In the femoropopliteal segment, drug-coated balloon (DCB) angioplasty and bare-metal stent (BMS) implantation are the methods of choice. In long lesions, spot-stenting should be preferred. For treatment of in-stent restenosis, DCB have proven their effectiveness. In severely calcified or dissected lesions, BMS are well suited. Infrapopliteal lesions should be revascularized to provide in-line flow to the foot through the target arterial path. According to current evidence, DCB or drug-eluting stents are more effective than plain old balloon angioplasty or BMS.
Authors: Kim Taeymans; Erik Groot Jebbink; Suzanne Holewijn; Jasper M Martens; Michel Versluis; Peter C J M Goverde; Michel M P J Reijnen Journal: J Vasc Surg Date: 2017-11-21 Impact factor: 4.268
Authors: Stefan Müller-Hülsbeck; Koen Keirse; Thomas Zeller; Herman Schroë; Juan Diaz-Cartelle Journal: Cardiovasc Intervent Radiol Date: 2017-09-25 Impact factor: 2.740
Authors: Victor Aboyans; Jean-Baptiste Ricco; Marie-Louise E L Bartelink; Martin Björck; Marianne Brodmann; Tina Cohnert; Jean-Philippe Collet; Martin Czerny; Marco De Carlo; Sebastian Debus; Christine Espinola-Klein; Thomas Kahan; Serge Kownator; Lucia Mazzolai; A Ross Naylor; Marco Roffi; Joachim Röther; Muriel Sprynger; Michal Tendera; Gunnar Tepe; Maarit Venermo; Charalambos Vlachopoulos; Ileana Desormais Journal: Eur Heart J Date: 2018-03-01 Impact factor: 29.983
Authors: M Piazza; F Squizzato; A Dall'Antonia; S Lepidi; M Menegolo; F Grego; M Antonello Journal: Eur J Vasc Endovasc Surg Date: 2017-05-06 Impact factor: 7.069
Authors: Michael D Dake; Gary M Ansel; Michael R Jaff; Takao Ohki; Richard R Saxon; H Bob Smouse; Lindsay S Machan; Scott A Snyder; Erin E O'Leary; Anthony O Ragheb; Thomas Zeller Journal: Circulation Date: 2016-03-11 Impact factor: 29.690